Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 3:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 113 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hypertension Stage 1 Clear all
Completed Phase 1Phase 2 Interventional

A Phase 1/2 Multicenter, Randomized, Study to Evaluate the Safety and Efficacy of VS101 Subconjunctival Latanoprost Insert in Subjects With Open-Angle Glaucoma or Ocular Hypertension

NCT02129673
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
VS101 Insert Dose A, VS101 Insert Dose B, VS101 Insert Dose C, Latanoprost 0.005% eye drops
Drug
Lead sponsor
ViSci Ltd.
Industry
Eligibility
18 Years to 85 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Bellevue, Washington
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Oct 30, 2026, 3:01 PM EDT
Completed Phase 1 Interventional

To Assess the Effect of Naproxcinod Versus Naproxen and Ibuprofen on Arterial Blood Pressure in Osteoarthritis Patients With Controlled Essential Hypertension

NCT00662896
View directory record Official record
Conditions
Osteoarthritis, Hypertension
Interventions
naproxcinod 375 mg bid, naproxcinod 750 mg bid, naproxen 250 mg bid, naproxen 500 mg bid, ibuprofen 600 mg tid
Drug
Lead sponsor
NicOx
Industry
Eligibility
40 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
57
States / cities
Birmingham, Alabama • Huntsville, Alabama • Sierra Vista, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2011 · Synced Oct 30, 2026, 3:01 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

TEPH: Telaglenastat Efficacy in Pulmonary Hypertension

NCT07223528
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Telaglenastat
Drug
Lead sponsor
Chan, Stephen, MD, PhD
Other
Eligibility
18 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 30, 2026, 3:01 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and IOP-Lowering Effects of WB007

NCT04149899
View directory record Official record
Conditions
Glaucoma, Primary Open Angle, Ocular Hypertension
Interventions
WB007 0.05%, WB007 0.15%, WB007 0.4%, Timolol 0.5%
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Oct 30, 2026, 3:01 PM EDT
Completed Phase 4 Interventional Results available

A Study on the Efficacy and Safety of Nebivolol Monotherapy in Hispanic Hypertensive Patients

NCT00770861
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 80 Years
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
29
States / cities
Buena Park, California • Chino, California • Long Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2011 · Synced Oct 30, 2026, 3:01 PM EDT
Completed Not applicable Interventional

Effects of Cocoa on Ambulatory Blood Pressure and Vascular Function in Patients With Stage I Hypertension

NCT01672840
View directory record Official record
Conditions
Hypertension
Interventions
5g Cocoa Consumption, 10g Cocoa Consumption
Dietary Supplement
Lead sponsor
Griffin Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Derby, Connecticut • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Oct 30, 2026, 3:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study to Determine the Metabolism and Clearance of Baxdrostat

NCT05961384
View directory record Official record
Conditions
Hypertension
Interventions
baxdrostat
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Oct 30, 2026, 3:01 PM EDT
Completed Phase 4 Interventional

Efficacy and Safety of Nebivolol Versus Metoprolol in Hypertensive Subject Taking Amlodipine

NCT03635125
View directory record Official record
Conditions
JNC 7 Stage 1 or 2 Hypertension
Interventions
Nebivolol I, Nebivolol II, Baseline Washout Phase
Drug · Other
Lead sponsor
Trinity Hypertension & Metabolic Research Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Carrollton, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Oct 30, 2026, 3:01 PM EDT
Completed Not applicable Interventional

Weight Inclusive and Adaptive Strategies to Enhance Cardiometabolic Health in Black Adults

NCT06284681
View directory record Official record
Conditions
Obesity, Prehypertension, Hypertension, PreDiabetes, Type 2 Diabetes, Dyslipidemia
Interventions
Weight-focused health coaching, Weight-neutral health coaching, Intensify lifestyle approach, Augment with enhanced medical management
Behavioral · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 30, 2026, 3:01 PM EDT
Completed Phase 4 Interventional Results available

A Study of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Stage I and Stage II Hypertension

NCT00430638
View directory record Official record
Conditions
Hypertension
Interventions
olmesartan medoxomil + hydrochlorothiazide, if necessary, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
29
States / cities
Birmingham, Alabama • Mobile, Alabama • Muscle Shoals, Alabama + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Oct 30, 2026, 3:01 PM EDT
Completed Phase 1Phase 2 Interventional

A Study of PER-001 in Participants With Open-Angle Glaucoma

NCT05822245
View directory record Official record
Conditions
Open-angle Glaucoma
Interventions
PER-001 Intravitreal Implant - Low Dose, PER-001 Intravitreal Implant - High Dose, PER-001 Intravitreal Implant - Sham
Drug
Lead sponsor
Perfuse Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 30, 2026, 3:01 PM EDT
Completed Phase 1Phase 2 Interventional Results available

H-1337 Ophthalmic Solution Phase 1/2

NCT03452033
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
H-1337 Placebo, H-1337 [1], H-1337 [2], H-1337 [3]
Drug
Lead sponsor
Allysta Pharmaceutical
Industry
Eligibility
18 Years to 99 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Goose Creek, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Oct 30, 2026, 3:01 PM EDT
Completed Not applicable Interventional

Hypertensive Ambulatory Trial to Compare the Efficacy of HCTZ and Lisinopril

NCT01258764
View directory record Official record
Conditions
Hypertension, Grade 1, Hypertension Treatment, N of 1 Study Design, Hypertension
Interventions
Lisinopril, Hydrochlorothiazide
Drug
Lead sponsor
Scripps Translational Science Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Oct 30, 2026, 3:01 PM EDT
Completed Phase 2 Interventional

Blueberry Consumption Improves Vascular Function and Lowers Blood Pressure in Postmenopausal Women With Pre- and Stage 1-hypertension

NCT01686282
View directory record Official record
Conditions
Blood Pressure
Interventions
Freeze-dried Blueberry Powder, Placebo
Dietary Supplement
Lead sponsor
Florida State University
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Jan 14, 2015 · Synced Oct 30, 2026, 3:01 PM EDT
Completed Not applicable Interventional

Blueberries for Improving Vascular Endothelial Function in Postmenopausal Women With Elevated Blood Pressure

NCT03370991
View directory record Official record
Conditions
Menopause, Elevated Blood Pressure, Hypertension, Endothelial Dysfunction
Interventions
Blueberry Powder, Placebo Powder
Dietary Supplement
Lead sponsor
Colorado State University
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 14, 2022 · Synced Oct 30, 2026, 3:01 PM EDT
Terminated Phase 3 Interventional Results available

Study of Ralinepag on Exercise Capacity by Cardiopulmonary Exercise Testing (CPET) in WHO Group 1 PH Subjects

NCT04084678
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Interventions
Ralinepag, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
Tucson, Arizona • Aurora, Colorado • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 30, 2026, 3:01 PM EDT
Completed Phase 1 Interventional Results available

Phase 1/1b Study With Nab-sirolimus for Patients With Severe Pulmonary Arterial Hypertension

NCT02587325
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
nab-sirolimus
Drug
Lead sponsor
Aadi Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
6
States / cities
Tucson, Arizona • Torrance, California • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Oct 30, 2026, 3:01 PM EDT
Completed Phase 3 Interventional

Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension

NCT01508026
View directory record Official record
Conditions
Stage 1 Hypertension, Stage 2 Hypertension
Interventions
Nebivolol and Valsartan 1, Nebivolol and Valsartan 2, Nebivolol and Valsartan 3, Nebivolol 1, Nebivolol 2, Valsartan 1, Valsartan 2, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
4,161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
413
States / cities
Birmingham, Alabama • Foley, Alabama • Gulf Shores, Alabama + 290 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2014 · Synced Oct 30, 2026, 3:01 PM EDT
Completed Not applicable Interventional

Water-only Fasting in the Treatment of Hypertension Patients

NCT04515095
View directory record Official record
Conditions
Hypertension
Interventions
Water-only Fasting
Other
Lead sponsor
TrueNorth Health Foundation
Other
Eligibility
30 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Santa Rosa, California
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 30, 2026, 3:01 PM EDT
Completed Phase 3 Interventional

Combination of Nebivolol and Valsartan Given as Free Tablets for Stage 1 or Stage 2 Hypertension

NCT01415505
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol, Valsartan and Hydrochlorothiazide
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
812 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
135
States / cities
Birmingham, Alabama • Foley, Alabama • Gulf Shores, Alabama + 113 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Oct 30, 2026, 3:01 PM EDT
Completed Phase 3 Interventional Results available

One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension

NCT00695955
View directory record Official record
Conditions
Hypertension
Interventions
Azilsartan medoxomil with or without add-on chlorthalidone, Azilsartan medoxomil with or without add-on hydrochlorothiazide
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
669 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
39
States / cities
Ozark, Alabama • Tallassee, Alabama • Long Beach, California + 36 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2011 · Synced Oct 30, 2026, 3:01 PM EDT
Completed Not applicable Interventional

The Penn Lifestyle Modification and Blood Pressure Study

NCT00328666
View directory record Official record
Conditions
Hypertension
Interventions
Iyengar yoga, Enhanced nutritional care classes
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 25, 2015 · Synced Oct 30, 2026, 3:01 PM EDT
Completed Phase 1 Interventional

Study of ST266 Given by Intranasal Delivery in Glaucoma Suspect Subjects

NCT03901781
View directory record Official record
Conditions
Ocular Hypertension
Interventions
ST266 via Intranasal Delivery
Combination Product
Lead sponsor
Noveome Biotherapeutics, formerly Stemnion
Industry
Eligibility
20 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Oct 30, 2026, 3:01 PM EDT
Completed Phase 3 Interventional Results available

Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure

NCT00624065
View directory record Official record
Conditions
Hypertension
Interventions
carvedilol controlled release/lisinopril, lisinopril + placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
76
States / cities
Mobile, Alabama • Chandler, Arizona • Glendale, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Oct 30, 2026, 3:01 PM EDT